LON:SALV - SalvaRx Group Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
GBX 11.50 -1.00 (-8.00 %)
(As of 03/25/2019 02:01 PM ET)
Previous CloseGBX 12.50
Today's RangeGBX 10 - GBX 12.75
52-Week RangeGBX 10 - GBX 93
Volume16,620 shs
Average Volume49,570 shs
Market Capitalization£4.22 million
P/E Ratio-1.64
Dividend YieldN/A
BetaN/A
SalvaRx Group plc discovers and develops immune-oncology drugs. The company is based in Ramsey, Isle of Man.

Receive SALV News and Ratings via Email

Sign-up to receive the latest news and ratings for SALV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-1624-811611

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowGBX 2.76 per share
Book ValueGBX (3.50) per share

Profitability

Miscellaneous

Employees2
Market Cap£4.22 million
Next Earnings DateN/A
OptionableNot Optionable

SalvaRx Group (LON:SALV) Frequently Asked Questions

What is SalvaRx Group's stock symbol?

SalvaRx Group trades on the London Stock Exchange (LON) under the ticker symbol "SALV."

Has SalvaRx Group been receiving favorable news coverage?

Media stories about SALV stock have been trending positive on Monday, InfoTrie Sentiment Analysis reports. InfoTrie scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. SalvaRx Group earned a news sentiment score of 3.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days.

Who are some of SalvaRx Group's key competitors?

What other stocks do shareholders of SalvaRx Group own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SalvaRx Group investors own include Premier African Minerals (PREM), Allergy Therapeutics (AGY), Solo Oil (SOLO), Cradle Arc (CRA), Active Energy Group (AEG), AutoZone (AZO), SOCO International (SIA), Velocys (VLS), Cora Gold (CORA) and Mercantile Ports & Logistics (MPL).

Who are SalvaRx Group's key executives?

SalvaRx Group's management team includes the folowing people:
  • Mr. Denham Hervey Newall Eke, CFO & Director (Age 67)

How do I buy shares of SalvaRx Group?

Shares of SALV and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is SalvaRx Group's stock price today?

One share of SALV stock can currently be purchased for approximately GBX 11.50.

How big of a company is SalvaRx Group?

SalvaRx Group has a market capitalization of £4.22 million. SalvaRx Group employs 2 workers across the globe.

What is SalvaRx Group's official website?

The official website for SalvaRx Group is https://www.salvarx.io/investors/aim-rule-26.html.

How can I contact SalvaRx Group?

SalvaRx Group's mailing address is Commerce House, 1 Bowring Road, RAMSEY, RAMSAY, IM8 2LQ, Isle of Man. The company can be reached via phone at +44-1624-811611.


MarketBeat Community Rating for SalvaRx Group (LON SALV)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  120 (Vote Outperform)
Underperform Votes:  93 (Vote Underperform)
Total Votes:  213
MarketBeat's community ratings are surveys of what our community members think about SalvaRx Group and other stocks. Vote "Outperform" if you believe SALV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SALV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/25/2019 by MarketBeat.com Staff

Featured Article: Capital Gains

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel